Incyte Corporation Share Price

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 12/07/2024 BST 5-day change 1st Jan Change
63.66 USD +2.20% Intraday chart for Incyte Corporation +11.04% +1.39%
Sales 2024 * 4.08B 314B Sales 2025 * 4.5B 346B Capitalization 14.31B 1,102B
Net income 2024 * 807M 62.12B Net income 2025 * 955M 73.51B EV / Sales 2024 * 2.57 x
Net cash position 2024 * 3.83B 295B Net cash position 2025 * 5.41B 416B EV / Sales 2025 * 1.98 x
P/E ratio 2024 *
18.2 x
P/E ratio 2025 *
15.3 x
Employees 2,524
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.27%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.20%
1 week+11.04%
Current month+5.01%
1 month+1.55%
3 months+18.22%
6 months+1.47%
Current year+1.39%
More quotes
1 week
57.17
Extreme 57.17
63.93
1 month
56.75
Extreme 56.75
64.30
Current year
50.35
Extreme 50.3498
67.37
1 year
50.27
Extreme 50.27
67.37
3 years
50.27
Extreme 50.27
86.29
5 years
50.27
Extreme 50.27
110.37
10 years
43.86
Extreme 43.86
153.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 12/01/14
Director of Finance/CFO 53 10/02/19
Chief Tech/Sci/R&D Officer 57 01/03/15
Members of the board TitleAgeSince
Director/Board Member 57 31/12/00
Director/Board Member 71 15/12/19
Director/Board Member 70 19/01/15
More insiders
Date Price Change Volume
12/07/24 63.66 +2.20% 1,934,890
11/07/24 62.29 +2.57% 2,268,682
10/07/24 60.73 +0.05% 2,525,127
09/07/24 60.7 +4.35% 2,408,353
08/07/24 58.17 +1.47% 2,669,763

Delayed Quote Nasdaq, July 12, 2024 at 09:00 pm

More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
63.66 USD
Average target price
72.66 USD
Spread / Average Target
+14.14%
Consensus